3:00 p.m. 2:00 p.m. 3:30 p.m. 4:30 p.m. Break Afternoon February 26, 2004 Concurrent Sessions Standard Operating Procedures for Human Research Compliance.

Slides:



Advertisements
Similar presentations
Tips to a Successful Monitoring Visit
Advertisements

The IND and Clinical Trial Management Frances Richmond Director International Center for Clinical Trials.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Good Clinical Practices Regulatory Guidelines for the Conduct of Clinical research Introduction to Research Pharmacy Services Javier Palacios, R.Ph. Sponsored.
ORD Human Research Protection K. Lynn Cates, MD Assistant Chief Research & Development Officer February 25, 2004.
Capturing and Reporting Adverse Events in Clinical Research
Hospital Pharmacy Payam Parchamazad, PharmD Staff Pharmacist
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
YALE MASTER SLIDE HERE Clinical Research Management – Is not just a handshake deal? Jamie Caldwell, MBA Director Office of Research Services for the Health.
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Demystifying the Competency Conundrum Facilitated by : Sylvia McKee, MN, RN, BC Coordinator, Clinical Staff Development & Education VA Salt Lake City Health.
Reality vs Urban Myth: The Truth About Regulations
Coordinator University Clinical Research Pharmacy Investigational Drug Service (IDS) Marjorie Shaw Phillips, MS, RPh, FASHP Clinical Research Pharmacist.
CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.
Response to FDA Audit 483 MX-4501N : Nine Category 483 Citations Meetings Minutes: Votes for, against, abstention and reason not recorded;
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
Yesterday, today, and tomorrow
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Compliance Issues for Medical Research at Healthcare Systems Jerry Castellano, Pharm.D., CIP Corporate Director Institutional Review Board Christiana Care.
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
ORO Reviews: Frequent Findings Related to IRBs Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight.
Research Auditing Presented by: Darlene Krueger, MBA RN CCRA Chief, GCP Auditing & Training VA Cooperative Studies Program Albuquerque, NM.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
ORO Reviews: Frequent Findings Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight May, 2012.
Research Compliance: An Overview of the Players and Issues Involved in Emory’s Research Compliance Programs.
Questions: AAHRPP Evaluation Instrument for Use with Final Revised Accreditation Standards Presented by: C. Karen Jeans, MSN, CCRN, CIP COACH Program Analyst,
Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements Revised May 21, 2010 (Presentation prepared for HRPP 101,
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious Diseases.
September 12, 2004 Simplifying the Administration of HIPAA Security Angel Hoffman, RN, MSN Director, Corporate Compliance University of Pittsburgh Medical.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Belinda Seto, Ph.D. Acting Deputy Director for Extramural Research National Institutes of Health Human Subjects Research Enhancements Awards Renaissance.
6/7/041 Seeking To Improve Human Research Protections through Accreditation John H. Mather MD Director, ORCR, OVPR.
Office of Research & Development (ORD) Local Accountability of Research 2009 Baltimore, Maryland January 13-14, 2009 “Meeting the Current Challenges of.
Human Research Protection Program & IRB Responsibilities Marisue Cody, PhD Director Center on Advice & Compliance Help.
Office of Research Oversight 1 ORO Research Suspensions and Other ACOS/R Concerns Tom Puglisi, PhD Local Accountability in Research April 8, 2010.
Integrating a Federated Healthcare Data Query Platform With Electronic IRB Information Systems Shan He IPHIE 2010.
OBSERVED IN ORO REVIEWS COMPLIANCE ISSUES: OBSERVED IN ORO REVIEWS David A. Weber, Ph.D., FACNP Acting Chief Officer Office of Research.
Guidance Training CFR §483.75(i) F501 Medical Director.
Continuing Review Presented by: Karen Jeans, PhD, CCRN, CIP Program Analyst, COACH.
VHA Research Compliance Reporting Requirements ORD Accreditation Conference Call December 15, 2011.
AAHRPP ACCREDITATION (Association for the Accreditation of Human Protection Programs)
Office of Research Oversight 1 Core Responsibilities for Human Research Protection Research Compliance Officers Robert Brooks, MD, PhD, MBA Associate Director,
Office of Research Oversight 1 Office of Research and Development Local Accountability Meeting January 2009.
1 Auditing and Monitoring Gerald Beccia/RCO VA CT Healthcare System.
Paul Kelly Facility Research Compliance Officer for the Ralph H. Johnson VA Medical Center.
Office of Human Research Protection Georgia Health Sciences University.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.
INVESTIGATOR RESPONSIBILITIES C. Karen Jeans, MSN COACH Project Analyst.
Durham VA Medical Center Animal Research Program Lessons Learned.
Office of Research & Development (ORD) Local Accountability of Research 2009 Baltimore, Maryland January 13-14, 2009 “Meeting the Current Challenges of.
VA Central IRB K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs.
VA Central IRB K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs September.
VA Central IRB MOU Webinar K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs.
Research Policy: ORD & ORO Working Together Brenda Cuccherini, PhD Office of Research & Development & Tom Puglisi, PhD Office of Research Oversight.
Marianne M. Elliott Office of Research Integrity and Ethics Bureau of Medicine and Surgery U. S Navy.
Good Clinical Practices and Best Research Practices at MU Health Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic.
CIS 170 MART Teaching Effectively/cis170mart.com FOR MORE CLASSES VISIT HCS 430 OUTLET Inspiring Minds/hcs430outlet.com FOR MORE CLASSES.
RESEARCH OVERSIGHT AT TULANE UNIVERSITY BRIAN J. WEIMER, JD TULANE UNIVERSITY RESEARCH COMPLIANCE OFFICER February 23, 2015.
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
Brown Bag Series First Tuesday of each month (except July)
Elements of an Organized Regulatory Binder
Timothy B. Cleary, Esq. Meredith Manning, Esq.
PEARLS Overview and Research Team Management
Presentation transcript:

3:00 p.m. 2:00 p.m. 3:30 p.m. 4:30 p.m. Break Afternoon February 26, 2004 Concurrent Sessions Standard Operating Procedures for Human Research Compliance Officers Speaker: Karen Jeans, MSN, RN This session addresses the regulatory requirements together with hints and practical tips that are not defined in writing. Topics cover developing standard operating procedures for electronic, paper, and verbal communications, auditing procedures, and archiving. Pharmacists Responsibilities in Clinical Studies Speakers: Mike Sather, PhD, CSP Crystal Harris, PharmD, CSP This session addresses pharmacists’ involvement and responsibilities in clinical studies involving drugs and devices. It will include the responsibilities of investigators and identify where the research pharmacist fits in. Organizational Structures for RCOs Moderator: Marisue Cody, PhD, RN Panel Members: Ellen Graf-Jansen, RCO, Cincinnati Angela Lacy, RCO, Portland Mindi Styn, RCO, Pittsburgh Virginia Wiley, RCO, Nashville A variety of issues regarding organizational relationships for RCOs will be addressed in this session. The panel will provide insight and experiences with different models, what works, what doesn’t and future directions for RCOs in the VA. The Regulatory Aspects of Adverse Medical Events and the Use of MedDRA in Coding Adverse Medical Events Speaker: Kathleen Swanson, RPh, MS, CSP Reporting and monitoring adverse events in clinical trials in order to protect patient safety is the responsibility of many individuals. The focus of this presentation will be to outline the roles of the investigator, IRB and sponsor in adverse medical events and how these roles are facilitated through individuals at the medical center. A summary of key regulations and policies involving adverse events will be presented. A brief discussion of the Medical Dictionary for Regulatory Activities (MedDRA) will be provided. Research Compliance OfficersResearch Pharmacists Administrative Officers Animal Research Update on AAALAC, IACUC/SRS, and Speaker: Michael Fallon, DVM, PhD This session will summarize important trends in AAALAC mandatory citations, provide some ideas for preventing duplication of review efforts between the IACUC and the SRS (Subcommittee on Research Safety; also known as the Institutional Biosafety Committee, or IBC), and cover important new features of VHA Handbook , "Use of Animals in Research." Contracting Speaker: M. Brenda Hebert This session will provide information on the different types of contracts that are used in the research setting. Participants will learn how to prepare a statement of work and the elements that should be incorporated into a well-constructed contract.

10:30 am 9:30 am 11:00 am 12:00 p.m. Break Morning February 27, 2004 Concurrent Sessions FDA Regulations Part 1 Speaker: Carolyn Hommel, FDA This session will address basic regulatory requirements for FDA regulated research. Topics will include: The informed consent process and documentation; protocol non- adherence: deviations and violations; adverse event reporting: sponsors, IRB, FDA; investigational drug accountability: dispensing, storage and documentation; and source documentation: accuracy and reproducibility. FDA Regulations Part 2 Speaker: Carolyn Hommel, FDA This session is a continuation of part 1. Time will be left for questions and answers. Research Compliance OfficersResearch Pharmacists & Administrative Officers Demystifying the Competency Conundrum Speaker: Sylvia McKee, MN, RN, BC Coordinator, Clinical Staff Dev. & Education, VA Salt Lake City Health Care System This session will help solve the mystery of competency assessment by discussing the process of establishing a high-quality competency program in the research setting. A high quality competency program is required to satisfy the JCAHO requirement that every staff member of a healthcare organization is competent to perform his/her job. Biosafety and Security Speaker: Brenda Cuccherini, PhD This session will provide an update on the revision to VHA Directive "Control of Hazardous Materials“. It will include discussion regarding the difference between biosafety and biosecurity, why both are important and how they are complementary. Other issues that will be discussed include: The role of the biosafety officer and responsible official, coordination and interaction with other medical center offices including the VA Police, the facility's/VISN IH staff, and site visits.

2:30 p.m. 1:30 p.m. 3:00 p.m. 4:00 p.m. Break Afternoon February 27, 2004 Concurrent Sessions Overview of ORO and the Common Rule Speakers: David A. Weber, PhD, ORO Joan Porter, DPA, MPH, ORO This session will provide an overview of the restructuring of ORO and their oversight responsibilities including audits, reporting requirements, and handling of research misconduct. This will be followed by a fundamental walkthrough of 38 CFR part 16 with reference to VHA handbook NCQA Accreditation and Research Pharmacies Speakers: Jessica Briefer French, NCQA Karen Jeans, MSN, RN As part of the VA Human Research Accreditation Protection Program, NCQA evaluation of the investigational pharmacy is a critical component. This session will examine VA regulations described in M-2, Part VII and describe the NCQA evaluation of the regulations during the on-site survey visit. Affiliate IRB and NCQA Accreditation Speakers: Jessica Briefer French, NCQA This session will address frequently asked questions by VA research programs that use affiliate IRBs to review their research. Such questions include: What are the VA responsibilities in providing oversight of the affiliate IRB? What are the affiliate responsibilities in the NCQA accreditation survey process? What happens if the affiliate IRB does not receive accreditation from PHRP or AAHRPP? Panel Discussion: Research Pharmacist Issues Moderator: Karen Jeans Panel Members: Jennifer Mixon, RPh, Charleston Debra Mundie, RPh: Richmond Herschel Rayles, RPh, North Chicago VA Kathleen Swanson, RPh, Alburqueque A variety of topics concerning investigational pharmacists will be addressed in this session. Discussion will include experiences with the NCQA pharmacy on-site survey, cost impact evaluations, storage, accountability, and evolving regulations. Research Compliance OfficersResearch PharmacistsAdministrative Officers &